JP Morgan Maintains Overweight on Caris Life Sciences, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 87.6%

Neg 87.6% Neu 0% Pos 0%

JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and lowers the price target from $35 to $30.